通过阻断mercapturic acid路径载体的阻断,增强卵巢癌细胞中的碳白金敏感性
B Madhu Krishna1, Sravani K Ramisetty1, Pankaj Garg2
1Department of Medical Oncology, Beckman Research Institute, City of Hope Comprehensive Cancer Center and National Medical Center, Duarte, CA 91010, United States.
Carcinogenesis
|July 25, 2024
概括
抑制Ral结合/相互作用蛋白 (RLIP) 通过减少瘤生长和增加化疗敏感性,对卵巢癌治疗具有前途. 向RLIP提供了一种针对癌症的新疗法策略.
科学领域:
- 生物化学 生物化学
- 在瘤学瘤学.
- 药理学 药理学是指药理学的学科.
背景情况:
- 拉尔结合/相互作用蛋白 (RLIP) 是一种携带者,参与细胞对毒素和压力的保护.
- 癌细胞中较高的RLIP水平通过调节性性氧化脂质,有助于抗性功能.
- RLIP是mercapturic acid通路中的关键载体,与癌症细胞存活有关.
研究的目的:
- 研究抑制RLIP在卵巢癌 (OC) 的治疗潜力.
- 在OC模型中评估RLIP向剂的疗效,单独或与碳烯结合.
- 探索RLIP作为癌症治疗的新型治疗点.
主要方法:
- 使用了卵巢癌细胞系 (MDAH2774,OVCAR4,OVCAR8) 和人类异种移植.
- 使用RLIP反感和RLIP抗体来抑制RLIP功能.
- 评估RLIP抑制对细胞活力,碳白素敏感性和异种移植中的瘤进展的影响.
主要成果:
- 针对RLIP的向剂 (反意义,抗体) 显著降低了OC细胞的活力.
- 抑制RLIP增强了OC细胞对卡博普拉丁的敏感性.
- 通过反意义的RLIP耗尽导致已建立的OC异种移植中的快速和持续的缓解.
- RLIP抗体表现出与反感和强化卡博普拉丁在异种移植中的效果相似的疗效.
结论:
- RLIP是一种关键的载体蛋白,支持癌细胞生存.
- 抑制RLIP代表了卵巢癌的可行的治疗策略,可能独立于传统化疗.
- 向RLIP提供了一种新的方法,可以提高现有的癌症疗法,如碳白金的有效性.
相关概念视频
Targeted Cancer Therapies
7.5K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
7.5K
Treatment Resistant Cancers
3.3K
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.3K


